Accelerating Typhoid Conjugate Vaccine Introduction: What Can Be Learned From Prior New Vaccine Introduction Initiatives?


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
07 03 2019
Historique:
entrez: 8 3 2019
pubmed: 8 3 2019
medline: 29 5 2020
Statut: ppublish

Résumé

The health consequences of typhoid, including increasing prevalence of drug-resistant strains, can stress healthcare systems. While vaccination is one of the most successful and cost-effective health interventions, vaccine introduction can take years and require considerable effort. The Typhoid Vaccine Acceleration Consortium (TyVAC) employs an integrated, proactive approach to accelerate the introduction of a new typhoid conjugate vaccine to reduce the burden of typhoid in countries eligible for support from Gavi, the Vaccine Alliance. TyVAC and its partners are executing a plan, informed by prior successful vaccine introductions, and tailored to the nuances of typhoid disease and the typhoid conjugate vaccine. The iterative process detailed herein summarizes the strategy and experience gained from the first 2 years of the project.

Identifiants

pubmed: 30845328
pii: 5371228
doi: 10.1093/cid/ciy1118
pmc: PMC6405264
doi:

Substances chimiques

Typhoid-Paratyphoid Vaccines 0
Vaccines, Conjugate 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

S171-S176

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

Références

Lancet. 2010 Aug 21;376(9741):615-23
pubmed: 20692031
J Infect Dis. 2009 Nov 1;200 Suppl 1:S63-9
pubmed: 19817616
J Infect Dis. 2018 Nov 10;218(suppl_4):S188-S194
pubmed: 30304505
mBio. 2018 Feb 20;9(1):
pubmed: 29463654
PLoS Med. 2010 Mar 16;7(3):e1000249
pubmed: 20305714
Lancet. 2017 Dec 2;390(10111):2472-2480
pubmed: 28965718
Malawi Med J. 2016 Sep;28(3):108-114
pubmed: 27895844
Clin Vaccine Immunol. 2011 May;18(5):730-5
pubmed: 21411598
Soc Sci Med. 2007 Oct;65(8):1751-64
pubmed: 17644230
Vaccine. 2010 Oct 8;28(43):7123-9
pubmed: 20659515
Vaccine. 2014 Sep 15;32(41):5301-10
pubmed: 25092632
Vaccine. 2019 Jan 7;37(2):214-216
pubmed: 29661581
J Med Econ. 2017 Oct;20(10):1094-1106
pubmed: 28737468
Vaccine. 2012 Nov 6;30(48):6859-63
pubmed: 22989686
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S50-S58
pubmed: 30845320
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S96-S104
pubmed: 30845324
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S154-S160
pubmed: 30845321
Hum Vaccin. 2010 Dec;6(12):1021-4
pubmed: 21150269
Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S9-S16
pubmed: 26933028
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S67-S73
pubmed: 30845329
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S165-S170
pubmed: 30845331
Viral Immunol. 2018 Mar;31(2):109-113
pubmed: 29116892
Health Aff (Millwood). 2016 Feb;35(2):250-8
pubmed: 26858377
Nat Med. 2005 Apr;11(4 Suppl):S12-5
pubmed: 15812482
Vaccine. 2000 Dec 8;19(9-10):1026-37
pubmed: 11137236
Lancet. 2017 Sep 16;390(10100):1211-1259
pubmed: 28919117
Vet World. 2015 Jan;8(1):61-5
pubmed: 27046998
Vaccine. 1999 Nov 12;18(7-8):736-42
pubmed: 10547434
Clin Infect Dis. 2006 Jul 15;43(2):123-31
pubmed: 16779737
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S59-S66
pubmed: 30845330
J Health Popul Nutr. 2004 Sep;22(3):268-74
pubmed: 15609779
Clin Infect Dis. 2019 Mar 7;68(Suppl 2):S74-S82
pubmed: 30845333
Am J Trop Med Hyg. 2018 Sep;99(3_Suppl):4-9
pubmed: 30047370
Lancet. 2010 Aug 21;376(9741):606-14
pubmed: 20692030
Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S434-41
pubmed: 26553672
Curr Top Microbiol Immunol. 2002;267:11-48
pubmed: 12082986
Wkly Epidemiol Rec. 2007 Aug 10;82(32):285-95
pubmed: 17691162
Clin Infect Dis. 2015 Aug 1;61(3):393-402
pubmed: 25870324

Auteurs

Leslie P Jamka (LP)

Center for Vaccine Development and Global Health at the University of Maryland School of Medicine, Baltimore, MD.

Kenneth W Simiyu (KW)

Center for Vaccine Development and Global Health at the University of Maryland School of Medicine, Baltimore, MD.

Adwoa D Bentsi-Enchill (AD)

Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Aziza J Mwisongo (AJ)

Center for Vaccine Innovation and Access, PATH, Seattle, Washington.

Helen Matzger (H)

Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.

Anthony A Marfin (AA)

Center for Vaccine Innovation and Access, PATH, Seattle, Washington.

Andrew J Pollard (AJ)

Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom.

Kathleen M Neuzil (KM)

Center for Vaccine Development and Global Health at the University of Maryland School of Medicine, Baltimore, MD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH